Nektar Therapeutics
NKTR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000906709
In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 2 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Nektar Therapeutics changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 239 | 243 | +4 |
| Shares | 169.9M | 168.2M | −1.68M (−1.0%) |
| Value | $3.40B | $2.89B | −$509.8M (−15.0%) |
New holders (25)
Institutions that held Nektar Therapeutics at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (21)
Institutions that held Nektar Therapeutics at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Putnam Investments LLC | 381,600 | $7.63M |
| Candriam Luxembourg S.C.A. | 306,085 | $5.00M |
| Goodman Financial Corp | 106,238 | $2.13M |
| Man Group plc | 65,154 | $1.30M |
| Janus Henderson Group PLC | 58,826 | $1.18M |
| GAM Holding AG | 51,403 | $1.03M |
| Quantitative Investment Management, LLC | 39,828 | $796.0K |
| Jump Financial, LLC | 23,500 | $470.0K |
| Employees Retirement System of Texas | 21,150 | $423.0K |
| Cormorant Asset Management, LP | 20,000 | $400.0K |
| CIBC World Markets Corp | 19,562 | $391.0K |
| ETF Managers Group, LLC | 18,000 | $351.0K |
| Bayesian Capital Management, LP | 13,769 | $275.0K |
| Bridgewater Associates, LP | 11,063 | $221.0K |
| Burleson & Company, LLC | 1,612 | $32.0K |
| Certified Advisory Corp | 735 | $15.0K |
| Global Retirement Partners, LLC | 300 | $6.00K |
| West Oak Capital, LLC | 30 | $1.00K |
| RMR Wealth Builders | 67 | $1.00K |
| Standard Family Office LLC | 51 | $1.00K |
| Meridian Wealth Partners, LLC | 24 | $0 |